Is Meridian Bioscience profitable in 2026?

Meridian stopped disclosing financials after going private on January 31, 2023. Its last public results were FY2022 revenue of $333.0 million (November 22, 2022). Current profitability is undisclosed, though parent SD Biosensor reported narrowing operating and net losses in its March 18, 2025 filing.

Who owns Meridian Bioscience now?

Meridian is privately owned by South Korea's SD Biosensor (60%) and private-equity firm SJL Partners (40%), after an all-cash $1.53 billion deal at $34.00 per share closed on January 31, 2023, delisting Meridian from Nasdaq (former ticker VIVO).

What is Meridian Bioscience's FDA Warning Letter about?

On December 22, 2025 the FDA issued Warning Letter 720826 to Meridian's subsidiary Magellan Diagnostics, citing manufacturing and quality violations tied to LeadCare II blood-lead test kits following an August 2025 inspection. Unresolved responses could risk seizure, injunction, or civil penalties.

Could AI replace Meridian Bioscience's diagnostics products?

Unlikely for its core business. Meridian sells FDA/IVDR-cleared wet-chemistry reagents, antigens, antibodies, and enzymes plus physical test kits like LeadCare, which are not software-substitutable. AI exposure is limited to ancillary tasks such as documentation and regulatory-submission drafting, not the regulated products themselves.

Who is Meridian Bioscience's biggest competitor?

Meridian competes against much larger diagnostics incumbents including Thermo Fisher Scientific, Abbott, Danaher's Cepheid, Roche, QIAGEN, bioMerieux, and QuidelOrtho. Meridian is subscale versus these giants in molecular and immunoassay diagnostics, defending narrower niches like blood-lead testing and B2B reagent supply instead.

Has Meridian Bioscience had layoffs since going private?

No layoffs have been publicly reported. Meridian's own site states CEO Andy Kitzmiller (appointed October 16, 2025) leads a global organization of more than 800 employees, consistent with the company's staffing level holding steady or growing modestly since the January 2023 buyout.

Biotech tools companies · subsidiary of SD Biosensor, Inc. (with co-ownership by SJL Partners LLC) · United States

Meridian Bioscience, Inc.

meridianbioscience.com ↗

Private diagnostics maker known for LeadCare blood-lead tests and lab reagents.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from mid-2026 · Every call on the record Checkpoint: FDA Warning Letter 720826 on LeadCare II reaches closeout or escalates toward a consent decree

The call

Meridian's blood-lead niche stays protected by regulation and habit, but an open FDA Warning Letter, a shaky parent, and a fresh executive team leave its next chapter unwritten.

Meridian makes equipment and chemicals that labs use to test for lead in blood and to run other medical tests. The company has been around for nearly 50 years and has built relationships with hospitals and labs that are hard to replace, but now faces serious problems: the FDA issued a warning about one of its main products in December 2025, its biggest owner (SD Biosensor) is losing money and unstable, and the company just hired a new leadership team in October 2025 that has not yet proven itself. The critical question is whether Meridian can fix the FDA warning quickly, or if regulators will keep the company locked down for many months, which would give larger rivals like Thermo Fisher and Danaher the opening they need to take over its customers.

Why

AI pressure: None apparent. Blood-lead testing and reagent manufacturing run on chemistry and FDA clearances, not on models AI can replicate. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific, Abbott Laboratories, Danaher (Cepheid), Roche, QIAGEN, bioMerieux, QuidelOrtho. These larger diagnostics makers already sell competing molecular and point-of-care tests, squeezing Meridian's reagent and Alethia lines on price and reach. Could a giant copy it? Probably.

What protects it. LeadCare II holds a near-lock on point-of-care blood-lead testing, backed by decades of FDA clearance and public-health distribution ties.

What would change this call

FDA Warning Letter 720826 closed or escalated to consent decree by mid-2026. Shows whether regulatory tail risk on LeadCare II is resolved or worsening.
SD Biosensor reports return to sustained profitability in coming quarterly filings. Indicates whether majority owner can keep funding Meridian without capital strain.
CEO Kitzmiller announces a specific growth strategy or acquisition within 12 months. Shows whether new leadership has a coherent direction or is just holding the line.

Key numbers

Acquired by SD Biosensor/SJL Partners for $1.53B (2023-01-31)
DOJ settlement of $42M over Magellan Diagnostics matter (2024-05-21)
FY2022 consolidated revenue $333.0M, up 5% YoY (2022-11-22)

Named risks

Active FDA Warning Letter on LeadCare II could escalate to consent decree or forced divestiture. Severity: high
Parent SD Biosensor's financial volatility could constrain capital available to Meridian. Severity: medium
Entirely new C-suite installed October 2025 has no established track record yet. Severity: medium
Equity is illiquid phantom/synthetic units tied to an eventual SD Biosensor/SJL exit, not public-market upside. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	losing to	Meridian described as subscale in molecular/immunoassay lines versus this giant, per 2026-01-06 industry mapping
Danaher (Cepheid)	gaining on	Named direct molecular-diagnostics peer with far greater scale in 2026-01-06 competitor listing
QuidelOrtho	contesting	Direct rapid-testing and immunoassay peer with a heavily recurring revenue model, noted November 2025
QIAGEN	contesting	Named molecular diagnostics competitor in 2026-01-06 industry company mapping
bioMerieux	losing to	BioFire molecular platform cited as a stronger comparable competitor, per 2026-01-06 report
Biomerica	losing to	Recruited Meridian's former CEO Jack Kenny to its board on August 28, 2023

Questions people ask

Is Meridian Bioscience profitable in 2026?: Meridian stopped disclosing financials after going private on January 31, 2023. Its last public results were FY2022 revenue of $333.0 million (November 22, 2022). Current profitability is undisclosed, though parent SD Biosensor reported narrowing operating and net losses in its March 18, 2025 filing.
Who owns Meridian Bioscience now?: Meridian is privately owned by South Korea's SD Biosensor (60%) and private-equity firm SJL Partners (40%), after an all-cash $1.53 billion deal at $34.00 per share closed on January 31, 2023, delisting Meridian from Nasdaq (former ticker VIVO).
What is Meridian Bioscience's FDA Warning Letter about?: On December 22, 2025 the FDA issued Warning Letter 720826 to Meridian's subsidiary Magellan Diagnostics, citing manufacturing and quality violations tied to LeadCare II blood-lead test kits following an August 2025 inspection. Unresolved responses could risk seizure, injunction, or civil penalties.
Could AI replace Meridian Bioscience's diagnostics products?: Unlikely for its core business. Meridian sells FDA/IVDR-cleared wet-chemistry reagents, antigens, antibodies, and enzymes plus physical test kits like LeadCare, which are not software-substitutable. AI exposure is limited to ancillary tasks such as documentation and regulatory-submission drafting, not the regulated products themselves.
Who is Meridian Bioscience's biggest competitor?: Meridian competes against much larger diagnostics incumbents including Thermo Fisher Scientific, Abbott, Danaher's Cepheid, Roche, QIAGEN, bioMerieux, and QuidelOrtho. Meridian is subscale versus these giants in molecular and immunoassay diagnostics, defending narrower niches like blood-lead testing and B2B reagent supply instead.
Has Meridian Bioscience had layoffs since going private?: No layoffs have been publicly reported. Meridian's own site states CEO Andy Kitzmiller (appointed October 16, 2025) leads a global organization of more than 800 employees, consistent with the company's staffing level holding steady or growing modestly since the January 2023 buyout.

Timeline

2026-07Meridian receives Health Canada license for Alethia CMV assay
2026-06Meridian collaborates with 4bases on scalable NGS workflows
2026-02Meridian gets IVDR certification for Alethia molecular assay portfolio, launches DNA fragmentation kit
2025-12-22FDA issues Warning Letter 720826 to Magellan Diagnostics over LeadCare II violations
2025-10-16Andy Kitzmiller named CEO, Julie Smith CFO, Harald Ottenhoff EVP Life Science
2025-04-23Meridian launches enzyme-stabilization services for molecular diagnostics
2025-03-18Parent SD Biosensor reports 80% operating-loss reduction
2024-11-01Magellan Diagnostics wins CDC Lead Detect Prize
2024-05-21Magellan Diagnostics settles DOJ investigation for $42 million
2023-01-31SD Biosensor and SJL Partners complete $1.53B acquisition, Meridian delisted from Nasdaq

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation